TY - JOUR
T1 - Trends and determinants of calcium antagonist usage after acute myocardial infarction (the GISSI experience)
AU - Zuanetti, Giulio
AU - Latini, Roberto
AU - Avanzini, Fausto
AU - Franzosi, Maria Grazia
AU - Maggioni, Aldo P.
AU - Colombo, Fabio
AU - Nicolis, Enrico
AU - Mauri, Francesco
PY - 1996/7/15
Y1 - 1996/7/15
N2 - In the last decade, several clinical trials in patients with, or recovering from, acute myocardial infarction (AMI) have evaluated the role of calcium antagonists in affecting patients' prognosis. Results have been disparate, with evidence of possible harm, no effect, or some benefit, depending on the agent used. We evaluated how the evidence from these trials has influenced the pattern of prescription of calcium antagonists and assessed the important determinants of use of these agents in patients after AMI. We analyzed retrospectively the prescription of calcium antagonists at discharge in all patients recovering from AMI enrolled in 3 large randomized clinical trials (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto-1 [GISSI-1], GISSI-2, and GISSI-3) during the last 10 years. A progressive decrease in prescriptions for calcium antagonists was evident, from 47.2% in GISSI-1 to 35.1% in GISSI-2 to 19.0% in GISSI-3 (p
AB - In the last decade, several clinical trials in patients with, or recovering from, acute myocardial infarction (AMI) have evaluated the role of calcium antagonists in affecting patients' prognosis. Results have been disparate, with evidence of possible harm, no effect, or some benefit, depending on the agent used. We evaluated how the evidence from these trials has influenced the pattern of prescription of calcium antagonists and assessed the important determinants of use of these agents in patients after AMI. We analyzed retrospectively the prescription of calcium antagonists at discharge in all patients recovering from AMI enrolled in 3 large randomized clinical trials (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto-1 [GISSI-1], GISSI-2, and GISSI-3) during the last 10 years. A progressive decrease in prescriptions for calcium antagonists was evident, from 47.2% in GISSI-1 to 35.1% in GISSI-2 to 19.0% in GISSI-3 (p
UR - http://www.scopus.com/inward/record.url?scp=0030015791&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030015791&partnerID=8YFLogxK
U2 - 10.1016/S0002-9149(96)00249-4
DO - 10.1016/S0002-9149(96)00249-4
M3 - Article
C2 - 8712135
AN - SCOPUS:0030015791
VL - 78
SP - 153
EP - 157
JO - American Journal of Cardiology
JF - American Journal of Cardiology
SN - 0002-9149
IS - 2
ER -